Results 201 to 210 of about 291,495 (261)
Gene Factors and Serotypes Related to Polysaccharide and Protein-Based Candidate Vaccines Among <i>Streptococcus agalactiae</i> Isolates. [PDF]
Boyanov VS, Alexandrova AS, Gergova RT.
europepmc +1 more source
Research progress on multivalent genetically engineered vaccines against enterotoxigenic <i>Escherichia coli</i>. [PDF]
Li H, Yang Z, She Y, Xu C, Ding W.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Polysaccharides as vaccine adjuvants
Vaccine, 2018Adjuvant is a substance added to vaccine to improve the immunogenicity of antigens, and it can induce stronger immune responses and reduce the dosage and production cost of vaccine in populations responding poorly to vaccination. Adjuvants in development or in use mainly include aluminum salts, oil emulsions, saponins, immune-stimulating complexes ...
Beini, Sun +5 more
openaire +2 more sources
CONJUGATED POLYSACCHARIDE VACCINES
Infectious Disease Clinics of North America, 1999The joining of polysaccharide antigens to various proteins can result in increased immunogenicity of vaccines composed of such antigens. This article discusses conjugated polysaccharide vaccines for Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitis.
H, Ahmad, E K, Chapnick
openaire +2 more sources
C-POLYSACCHARIDE IN A PNEUMOCOCCAL VACCINE
Acta Pathologica Microbiologica Scandinavica Series C: Immunology, 2009The 14-valent pneumococcal vaccine, Pneumovax, was found to contain approximately 25o micrograms per ml of the cell-wall antigen, C-polysaccharide (C-Ps), in addition to 100 micrograms per ml of each of the 14 capsular polysaccharides. Rabbit anti-C-Ps antiserum recognized four components of this C-Ps with different antigenic determinants ...
U B, Sørensen, J, Henrichsen
openaire +2 more sources
Pneumococcal Polysaccharide Vaccines
Clinical Infectious Diseases, 1989Pneumococcal infections are major causes of morbidity and mortality in children throughout the world. For this reason and because of the increasingly frequent isolation of multiply resistant pneumococci of the serotypes most often causing infection in childhood, prophylactic immunization offers the best prospect of reducing the incidence of such ...
openaire +2 more sources
Vaccines Against Polysaccharide Antigens
Current Drug Target -Infectious Disorders, 2001Encapsulated bacteria such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae serogroup B (Hib) are a major cause of disease worldwide. Vaccine development against these organisms has targeted their capsular polysaccharides (CPS), as anti-capsular antibodies often protect against disease.
G B, Lesinski, M A, Westerink
openaire +2 more sources
Polysaccharide Conjugate Typhoid Vaccine
New England Journal of Medicine, 2001There is a growing appreciation of the huge health threat posed by increasingly resistant infectious diseases, especially in tropical areas of the developing world.
R L, Guerrant, M, Kosek
openaire +2 more sources
Vaccine, 2007
Asplenic children are at high risk of invasive pneumococcal infection. In this group, the American Academy of Pediatrics recommends a single revaccination with the 23-valent polysaccharide vaccine (PSV23) 3-5 years after a previous PSV23 dose. Despite potential advantages, there are few data available regarding the safety and immunogenicity of the ...
F, Smets +6 more
openaire +2 more sources
Asplenic children are at high risk of invasive pneumococcal infection. In this group, the American Academy of Pediatrics recommends a single revaccination with the 23-valent polysaccharide vaccine (PSV23) 3-5 years after a previous PSV23 dose. Despite potential advantages, there are few data available regarding the safety and immunogenicity of the ...
F, Smets +6 more
openaire +2 more sources
Efficacy of Pneumococcal Polysaccharide Vaccines
Clinical Infectious Diseases, 1981due to pneumococcal infection. Estimates based on data obtained in this country after licensure of the vaccine suggest that the efficacy in certain groups may be low:
openaire +2 more sources

